Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main Cure Vac N.V. Call Options Transaction History

Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main

$94.9 Billion
Q3 2024

Call Options

2 transactions

Quarter	Operation	Price Per call	calls change	calls Held	SEC Form
Q3 2023 Nov 14, 2023	BUY	$6.5 - $10.77 $1.85 Million - $3.07 Million	285,000 New	285,000 $1.95 Million
Q2 2021 Aug 16, 2021	BUY	$56.91 - $127.53 $11.1 Million - $24.9 Million	195,300 New	195,300 $14.4 Million

Others Institutions Holding CVAC

# of Institutions

Shares Held

12.3M

Call Options Held

164K

Put Options Held

117K

Israel Englander Millennium Management LLC | New York, Ny

2.42M
Shares

$6.43 Million
0.0% of portfolio
Black Rock Inc. New York, NY

2.25M
Shares

$6 Million
0.0% of portfolio
Bill & Melinda Gates Foundation Seattle, WA

1.57M
Shares

$4.17 Million
10.6% of portfolio
Ken Griffin Citadel Advisors LLC | Chicago, Il

1.01M
Shares

$2.69 Million
0.0% of portfolio
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct

780K
Shares

$2.07 Million
0.01% of portfolio

View Full List

About CureVac N.V.

Ticker CVAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,467,008
Market Cap $499M
Description
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...

More about CVAC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main, based on Form 13F filings with the SEC.

News

Stay updated on Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt Am Main with notifications on news.

Account